MALDI-TOF

Scientists from the Colorado School of Mines have proposed a method to complement mass spec-based protein profiling. 

While much attention has focused on triple quads, MALDI-TOFs offer advantages in simplicity and throughput that could help them make clinical inroads.

The UK firm is using MALDI-TOF mass spec technology to develop the test as a screening tool for the disorder as early as eight weeks into a pregnancy.

Researchers from the Public Health Agency of Sweden have developed an approach for typing Clostridium difficile isolates based on their patterns of high-molecular weight proteins.

MALDI mass spectrometry continues to make inroads into the microbiology market, with a growing number of researchers and clinicians adopting the technology for microbe identification.

NEW YORK (GenomeWeb News) – Ezose Sciences today said that it has signed an agreement to collaborate with Kyowa Hakko Kirin on glycomics studies using Ezose's GlycanMap platform.

NEW YORK (GenomeWeb News) – Bruker today announced it has licensed intellectual property from the Erasmus Medical Center for the rapid testing of beta-lactamase activity using MALDI-TOF technology.

Glycomics firm Ezose Biosciences said this week it has inked a collaboration agreement with Merck for biomarker discovery research in diabetes.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Bruker and Chungnam National University in South Korea announced today a collaboration to develop MALDI-TOF-based methodologies for the analysis of glycans.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.